Not sure if this was shared here but another paper

Quote:

---

Leronlimab is a humanized mAb and a C–C chemokine receptor type 5 (CCR5) antagonist. The CCR5 is located on T regulatory cells, dendritic cells, and macrophages, to mediate chemotaxis in response to its ligands (CCL3, CCL4, and CCL5) [70]. In SARS-CoV infection, macrophages and airway epithelial cells express high levels of chemokine ligand 5 (CCL5). Leronlimab by competitively binding to the CCR5 inhibits CCL5, thereby reducing the downstream release of pro-inflammatory cytokines and inhibiting the migration of T-regulatory cells to the site of infection are occurred [71]. A small study showed that Leronlimab decreases the increased plasma levels of IL-6 and CCL5, and normalized CD4/CD8 ratios in severe COVID-19 patients [72].

---